-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $25

Benzinga·05/16/2025 15:16:34
Listen to the news
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $23 to $25.